Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the stock.

Separately, Roth Mkm restated a “buy” rating and set a $40.00 price target on shares of Bio-Path in a report on Thursday, April 18th.

Bio-Path Stock Performance

Shares of BPTH opened at $2.64 on Wednesday. The firm has a market cap of $1.79 million, a price-to-earnings ratio of -0.06 and a beta of 0.35. Bio-Path has a 52-week low of $2.35 and a 52-week high of $44.80. The business’s fifty day moving average is $4.89 and its 200-day moving average is $8.38.

Bio-Path (NASDAQ:BPTH) last issued its earnings results on Friday, March 8th. The company reported ($5.40) earnings per share for the quarter, meeting analysts’ consensus estimates of ($5.40). During the same quarter last year, the business posted ($10.60) earnings per share. As a group, research analysts forecast that Bio-Path will post -18.71 EPS for the current fiscal year.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.